**Name of Journal:** *World Journal of Gastrointestinal Surgery*

**Manuscript NO:** 91003

**Manuscript Type:** MINIREVIEWS

**Applications of gastric peroral endoscopic myotomy in the treatment of upper gastrointestinal tract disease**

Chang SY *et al.* Recent advances of G-POME

Shi-Yu Chang, Guo-Hua Jin, Hai-Bo Sun, Dong Yang, Tong-Yu Tang

**Shi-Yu Chang, Guo-Hua Jin, Hai-Bo Sun, Dong Yang, Tong-Yu Tang,** Department of Gastroenterology, The First Hospital of Jilin University, Changchun 130021, Jilin Province, China

**Co-first authors:** Shi-Yu Chang and Guo-Hua Jin.

**Author contributions:** Chang SY and Jin GH wrote the paper, provided equal contributions to the article; Sun HB and Yang D collected relevant data and conducted analysis; Tang TY provided research directions and reviewed the paper; all the authors report no relevant conflicts of interest for this article. The completion of this paper is the result of the joint efforts and significant contributions of both authors, Chang SY and Jin GH. They have played an indispensable role at every stage of this research project, from the initial conceptualization and experimental design to data analysis and interpretation of results, as well as the final drafting and revision of the paper. Both authors have invested equal amounts of time and energy into the work. Their collaboration has been equal and close-knit, and thus, in this paper, Chang SY and Jin GH should be recognized as co-first authors.

**Corresponding author: Tong-Yu Tang, MD, Chief Physician,** Department of Gastroenterology, The First Hospital of Jilin University, No. 1 Xinmin Street, Changchun 130021, Jilin Province, China. tangty@jlu.edu.cn

**Received:** December 19, 2023

**Revised:** January 15, 2024

**Accepted:** February 8, 2024

**Published online:**

**Abstract**

Gastric peroral endoscopic myotomy (G-POME) is an emerging minimally invasive endoscopic technique involving the establishment of a submucosal tunnel around the pyloric sphincter. In 2013, Khashab *et al* used G-POME for the first time in the treatment of gastroparesis with enhanced therapeutic efficacy, providing a new direction for the treatment of gastroparesis. With the recent and rapid development of G-POME therapy technology, progress has been made in the treatment of gastroparesis and other upper digestive tract diseases, such as congenital hypertrophic pyloric stenosis and gastric sleeve stricture, with G-POME. This article reviews the research progress and future prospects of G-POME for the treatment of upper digestive tract gastrointestinal diseases.

**Key Words:** Gastric peroral endoscopic myotomy; Upper digestive tract diseases; Gastroparesis; Congenital hypertrophic pyloric stenosis; Gastric sleeve stricture

Chang SY, Jin GH, Sun HB, Yang D, Tang TY. Applications of gastric peroral endoscopic myotomy in the treatment of upper gastrointestinal tract disease. *World J Gastrointest Surg* 2024; In press

**Core Tip:** Since the application of gastric peroral endoscopic myotomy (G-POME) in gastroparesis in 2013, it has been widely promoted and applied by many centers. More and more centers are using G-POME to treat gastroparesis， congenital hypertrophic pyloric stenosis， and other upper gastrointestinal diseases. This article reviews the technological progress of G-POME and its application in upper gastrointestinal diseases.

**INTRODUCTION**

As a new endoscopic minimally invasive technique, gastric peroral endoscopic myotomy (G-POME) was first used to treat refractory gastroparesis by Khashab *et al*[1] in 2013. The technical basis of G-POME was established by Inoue *et al*[2] in 2010, who applied transoral endoscopic myotomy (POME) for the treatment of achalasia.As for POME, G-POME can be divided into four steps: mucosal incision and tunnel entry, submucosal tunneling, pyloromyotomy, and closure of mucosal entry. Since G-POME is associated with less trauma and fewer postoperative adverse reactions and has better short-term or long-term effects than traditional surgical methods, G-POME has been popularized worldwide, providing a new paradigm for the treatment of some refractory upper gastrointestinal diseases[3].

**Procedure of G-POME**

***Mucosal incision and tunnel entry***

The initial mucosal incision is usually made on the great curvature/posterior wall of the stomach, which is considered the easiest approach. After the gastric mucosa is cut, the tunnel can be established easily and close to the pyloric area. The use of a lesser curvature for the stomach/anterior wall approach has also been reported[4]. However, this method has the problem of difficult endoscopic localization. Although the approximate position can be determined by repeatedly withdrawing the endoscope, this approach adds many unnecessary steps compared with the conventional scheme. Similarly, Jovani *et al*[5] reported a new surgical approach involving simultaneous incision of the mucosa at both the greater and lesser curvatures of the stomach and double-tunnel standard myotomy. This new method improves G-POME.

Before the incision of the mucosa is made, submucosal vesicles are formed by injecting stained saline into the submucosa. A volume expander can be added to the injection to assist in incision of the mucosa and maintain the opening of the tunnel. Since route deviation easily occurs during the establishment of a tunnel under endoscopy, we need to avoid creating a longer tunnel. A longitudinal incision of 2 cm approximately 4-5 cm is made at the proximal end of the pylorus, the submucosal fibers are carefully peeled off at the entrance of the tunnel, and if necessary, the incision is sprayed or injected with indigo carmine salt solution and a hardening needle to strengthen the boundary between the submucosa and the lamina propria. According to a study of adverse events with G-POME[6], longitudinal mucosal incisions are significantly associated with a lower incidence of adverse reactions, suggesting that transverse mucosal incisions should be avoided to reduce possible adverse events. After the separation is completed, the endoscope is slowly introduced into the submucosal space.

***Submucosal tunneling***

After entering the submucosal space, the proper muscle layer is kept facing 6:00, and the mucous layer was kept facing 12:00 to ensure the correct direction of the tunnel. The fibers on the surface of the lamina propria are continuously stripped to establish a submucosal tunnel. When establishing the tunnel, care should be taken to avoid damaging the integrity of the mucosa. According to a meta-analysis by Stojilkovic *et al*[7], 62 of 835 patients who underwent G-POME experienced adverse events. In addition to the most common postoperative abdominal pain, bleeding and mucosal laceration often occur and may be related to intraoperative mucosal injury. Other complications associated with mucosal injury, such as capnoperitoneum[3,6,8] and delayed bleeding of gastric ulcers[9], have also been mentioned in a study of adverse events associated with G-POME. Other complications include delayed leakage and perforation, but the relationship between mucosal injury and these complications needs further study. Penetrating vessels are often observed in the proximal pylorus during endoscopy. Coagulation forceps should be used to prevent massive bleeding caused by vascular injury.

Endoscopic injection of blue saline (a mixture of methylene blue and saline) is repeatedly used to stain submucosal fibers during tunnel extension. This approach not only provides a protective pad for the mucosa but also outlines the lamina propria and helps to identify the pyloric muscle ring (PMR). Indeed, identification of the PMR is a very important step in G-POME, as it directly affects the efficacy of surgical treatment and the possibility of postoperative complications. The conventional way to locate the PMR is to pull the endoscope out of the tunnel, push it toward the pylorus and look for blue saline injected into the submucosa. However, Xue *et al*[10] determined the location of the PMR by placing an inner clip at the pylorus, providing an ingenious method for locating the PMR. This approach avoids the trauma that may be caused by the application of traditional methods and effectively shortens the time needed for surgery. In POME, in which a submucosal tunnel is established, Khashab *et al*[11] used a double endoscope to locate the gastroesophageal junction without withdrawing from the tunnel; this finding suggests that double endoscopy can also be used to locate the PMR in G-POME. The extension of the tunnel should be exposed behind the pyloric ring (a "crescent-shaped" thick muscle bundle under endoscopy). Since the duodenal mucosal layer is perpendicular to the pyloric ring, perforation of the mucosa can easily occur when crossing the pyloric ring and continuing to establish a submucosal tunnel; thus, extra care should be taken to avoid excessive extension of the tunnel.

***Pyloromyotomy***

After the pylorus is exposed, a full-thickness myotomy of the inner circular and oblique muscle bundles is performed starting 2 cm from the proximal end of the pylorus. Myoptosis is gradually performed during the operation to avoid damaging the serosal layer and abdominal viscera. The outer longitudinal muscle layer is often preserved to ensure separation from important surrounding structures, especially the larger vascular system around the duodenum. The myotomy is performed from the pylorus to the gastric antrum, with a length of 2 cm ± 1 cm. During the resection process, it is necessary to avoid making long incisions in the gastric antral circular muscle, as this may weaken the contraction function of the gastric antrum and reduce the pushing of food particles toward the pylorus, thus exacerbating the symptoms of gastroparesis[12].

In a 12-month follow-up study, Kia Vosoughi *et al*[13] tracked 80 patients who underwent G-POME surgery. The clinical success rate was 79% at 1 month and 56% at 12 months (clinical success was defined as a decrease in the average GCSI score of 1 point and a decrease in at least two subscale scores on the GCSI of 25%)[14]. A prospective study by Gonzalez *et al*[15] also showed that the clinical success rate of G-POME for treating gastroparesis decreases over time. These studies suggest that some patients have recurrent symptoms after G-POME surgery. This may be related to the relatively short distance between muscle fibers caused by standard myotomy, which increases the risk of muscle tissue remodeling during healing. In response to this situation, Jovani *et al*[5] reported two cases in which the risk of recurrence was reduced. In one patient, a pyloric myotomy was performed again on the right side of the first myotomy. The direction of the incision was parallel to the direction of the first myotomy, and the muscle fibers between the two pyloric myotomies were removed using a 10 mm cold ring cutter, thereby enlarging the distance between the edges of the muscle layers of the two incisions. The other patient had recurrent symptoms after undergoing standard G-POME, and double-tunnel G-POME was performed to establish a submucosal tunnel along both the greater curvature and lesser curvature of the stomach for myotomy. Although both improved G-POME procedures employed more extensive myotomy to circumvent potential muscle tissue remodeling and symptom recurrence, a comparison with the improvement in symptoms observed after conventional G-POME should be conducted to assess efficacy.

***Closure of mucosal entry***

After the pyloric muscle has been resected, the endoscope is carefully withdrawn from the tunnel. Subsequently, the mucosal incision is meticulously closed. Complete and secure closure of the mucosal entrance is a crucial step in this procedure, as it plays a pivotal role in preventing complications such as peritonitis and postoperative leakage. The commonly used closure techniques include endoscopic clips, endoscopic suture out-of-range ligation clips, and snares[16-19]. In most clinical centers where G-POME is performed, the most commonly employed closure method involves the use of endoscopic clips and sutures. Specifically, in POME, the mucosal incision is typically closed using endoscopic clips[2,12,20]. In G-POME, the thick mucosal layer can make it challenging to approach and grasp the mucosal cutting edge stably. This may cause difficulties in closing it with a clamp. Specifically, when the incision is wide, a larger clip is often needed to achieve closure.

In general, the method used to close the mucosal incision depends on the direction of the incision[21]. If the operator is more skilled at applying endoscopic clips and it is simpler to align the clip with longitudinal incisions, endoscopic clamp closure is the preferred method for closing longitudinal mucosal incisions. Nonetheless, Kahaleh *et al*[17], Xu *et al*[22], and others have also reported instances in which endoscopic clamp closure was unsuccessful, rendering endoscopic suturing an alternative option. Endoscopic suturing is considered safer and more effective than endoscopic clipping, but it places a heavier economic burden on patients. Additionally, endoscopic suturing takes longer (14.1 minutes *vs* 9.8 minutes). Although the total operation time for patients who undergo endoscopic clip placement tends to be shorter than that for patients who do not, there is no significant difference in the total operation time between the two methods. Furthermore, the shorter closing time of endoscopic clips does not translate into any economic benefits[16]. For the center of the incision to be closed with an endoscopic clip, remedial closure methods such as endoscopic suturing should be used. To avoid postoperative complications such as leakage or delayed bleeding of gastric ulcers due to poor closure of the mucosal entrance, combined endoscopic clamping and endoscopic suturing to close mucosal incisions have been used in some research centers, and good results have been achieved[23]. For centers in which G-POME is performed, the mucosal closure methods should be selected based on the actual situation of the patient during surgery. For patients for whom closure is difficult or poor when using a single method, the combination of endoscopic clips and endoscopic sutures is necessary (Table 1).

**G-POME for gastroparesis**

***Introduction to gastroparesis***

Gastroparesis is defined as delayed gastric emptying in the absence of mechanical obstruction. The most common causes of infection are diabetes, surgery, or infection, but it may also present as idiopathic gastroparesis. The pathogenesis of gastroparesis is not fully understood and may involve impaired gastric regulation, autonomic neuropathy, gastric contraction incoordination, pyloric dysfunction, degeneration of Cajal interstitial cells (ICCs), and neurohormone disorders[24-28]. Gastroparesis often presents with vague symptoms such as nausea, vomiting, early satiety, postprandial abdominal distension, and abdominal pain. In severe cases, patients may experience weight loss and malnutrition.

The diagnosis of gastroparesis requires three main criteria: (1) symptoms of gastroparesis, such as nausea, vomiting, early satiety, and postprandial abdominal distension; (2) absence of mechanical obstruction; and (3) obvious delayed gastric emptying[29] (Figure 1). Patients with symptoms of gastroparesis should undergo endoscopy to rule out obstruction and a gastric emptying examination to confirm the diagnosis of gastroparesis. The main symptom index (GCSI) of gastroparesis is often used to evaluate the clinical response; the quality-of-life assessment scale and gastrointestinal life index score are used to evaluate quality of life in patients with upper digestive tract diseases[30]. The gold standard method for evaluating delayed gastric emptying is based on the Tougas regimen, which involves a radiographic study of a 4-hour T99-labeled solid diet[29,31], with gastric emptying objectively measured according to the results of gastric emptying scintigraphy (GES). A clear diagnosis of gastroparesis requires certain equipment and technical support, and the gold standard for diagnosing this disease involves a radiological examination, which may cause concern for some female patients and cause them to reject diagnostic examination. Gastroparesis is more common in women, with a prevalence rate of approximately 37.8/100000 person-years, compared with 9.8/100000 person-years in men[32]. For these reasons, the true prevalence of gastroparesis is difficult to accurately assess, and many patients with gastroparesis are diagnosed with functional dyspepsia. Thus, the actual number of patients may be much greater than previously believed.

***Traditional treatment options for gastroparesis***

Dietary modifications and pharmacological interventions are the first-line treatments for gastroparesis, with approximately 70% of patients demonstrating adequate responses[33]. Gastric motility is a complex process involving the coordinated interaction of motor, secretory, and neuroregulatory activities[34], and single interventions are unlikely to effectively target the entire gastric emptying mechanism. Metoclopramide is currently the only drug approved by the U.S. Food and Drug Administration for the treatment of gastroparesis, but its severe extrapyramidal side effects limit its long-term use in patients with gastroparesis[35]. Domperidone, another D2 receptor antagonist similar to metoclopramide, can promote gastric emptying but may also lead to cardiovascular-related adverse effects[36]. Erythromycin is an antibiotic with prokinetic properties, but due to rapid tolerance, it does not improve symptoms well over a long period[37]. Other drugs, including 5-HT3 receptor antagonists such as ondansetron, 5-HT4 agonists such as prucalopride and cisapride, and growth hormone-releasing peptide receptor agonists such as phenothiazines and muscarinic receptor antagonists, have been used in the management of gastroparesis symptoms. Although these drugs can improve nausea and vomiting symptoms in patients, they have no significant effect on gastric emptying due to the association between abdominal bloating and early satiety with impaired gastric fundus regulation[38]. These limitations highlight the need for alternative treatment options for gastroparesis (Table 2).

For patients who do not respond to the conventional regimen, treatment strategies include peripyloric botulinum toxin injection, gastric electrical stimulation, surgery, and endoscopic intervention to disrupt the pyloric outlet, thereby improving gastric emptying and alleviating gastroparesis symptoms. Peripyloric botulinum toxin injection is highly anticipated to be useful for the treatment of gastroparesis[39]; however, although some studies seem to demonstrate the effectiveness of this treatment, randomized controlled trials have failed to show any improvement in symptoms[40]. According to a meta-analysis of gastric electrical stimulation for the treatment of gastroparesis, the clinical response rate at 24 months was 53.7%, and 56.5% of gastric electrical stimulation patients experienced clinical relapse within 2 years[41]. Furthermore, implantation of the device necessitates surgery, and only a limited number of centers possess expertise in both inserting and managing the device, presenting certain practical challenges for its widespread adoption. Surgical options include laparoscopic pyloroplasty and surgical pyloromyotomy. The clinical efficacy of laparoscopic pyloric ring myotomy for the treatment of gastroparesis is approximately 83%-86%, with approximately 60%-90% of patients reporting normalized gastric emptying[42]. However, laparoscopic pyloric ring myotomy is associated with adverse effects such as leakage, bleeding, and wound infection, which increase patient risk. Endoscopic methods include endoscopic pyloromyotomy and perpendicular surgical stent placement. Pyloric stent placement has been shown to effectively improve gastric emptying in patients[43], but it is associated with the risk of stent migration, which greatly increases the risk of requiring another surgery. Therefore, this approach is not considered a feasible long-term solution. Several studies have also applied temporary pyloric stents for the treatment of postoperative gastroparesis patients, with stent removal after symptom relief[44]. However, this approach may not be useful for long-term treatment in patients with refractory gastroparesis.

***G-POME for gastroparesis***

In 2013, Khashab *et al*[1] first used G-POME for the treatment of gastroparesis and achieved good results. Traditional pyloroplasty has been proven to effectively improve the clinical symptoms of nausea, vomiting, *etc.*, in patients with gastroparesis. Compared with other conventional surgical protocols, G-POME has a safer profile and relatively less invasiveness[42]. Thus, this approach has been affirmed and applied by many centers. The surgical success and postoperative adverse reaction rates of G-POME are similar to those of pyloroplasty[45], and the clinical success rates in terms of the GCSI score and quality of life are also similar[46]. However, as a new endoscopic surgery, G-POPE is minimally invasive and more acceptable to patients. In terms of surgical duration, the average G-POME surgery duration ranges from 33 to 120 min, while the average pyloroplasty duration ranges from 99 to 175 min[45]. A study on the learning curve of G-POME showed that as the number of operations performed increased, the time needed for the endoscopist to perform G-POME gradually decreased. After performing 18 operations, the surgical duration reached 60 minutes[47].For endoscopists with experience in POME, the time needed to master G-POME decreased. Hence, it is beneficial for centers with endoscopic operating conditions to carry out and promote G-POME such that more gastroparesis patients for whom drug and dietary management have failed can receive safe and effective treatment, reducing the problems caused by gastroparesis.

The safety and technical success rate of G-POME in the treatment of gastroparesis have been confirmed[14,39,48], with an overall incidence of adverse events ranging from 0% to 6.7%[4,18,49,50]. Serious adverse events include gastrointestinal bleeding, pyloric ulcers, and capnoperitoneum. One study reported an unusually high perforation rate (20%). This may have been due to the use of full-thickness pyloromyotomy[51,52], which is extremely rare in selective myotomy. With the promotion of G-POME and the follow-up studies on this procedure, its effectiveness has also been confirmed. During a 36-month follow-up period, significant improvements in symptoms and quality of life were observed in 73% to 85.7% of patients[53,54]. However, in some studies, a high overall effectiveness in refractory gastroparesis has not been shown for G-POME[13], which is mainly related to differences in the definition of clinical success. Many previous studies have defined clinical success as an improvement in the GCSI score, SF-36 score, or GES after G-POME surgery[14,18]. This study[13] defined clinical success as an average GCSI score reduction of 1 point and > 25%.

On the other hand, one study[13] suggested a guideline for the selection of gastroparesis patients who undergo G-POME surgery. G-POME is a novel procedure for targeting the pyloric sphincter and is expected to achieve good clinical results in patients with gastroparesis caused by pyloric spasm. Compliance and distension of the pylorus have been proven to be predictive of the clinical response to pyloric-directed therapy[51,55,56]. In addition, the severity of clinical symptoms at baseline and a gastric retention > 20% for 4 h before G-POME are independent predictive factors for clinical success[57]. Hence, for patients with severe symptoms and great GES retention, G-POEM should be considered a priority treatment for gastroparesis after conservative treatment has been proven to be ineffective. In addition, current research on the pathogenesis of gastroparesis has focused on ICCs. G-POME can be used to sample pyloric muscles during the procedure, thereby facilitating pathological studies of gastroparesis.

One of the latest advances in the endoscopic evaluation of gastroparesis is the use of intraluminal functional probe imaging (EndoFLIPⓇ) to measure impedance planes. EndoFLIPⓇ is being applied in G-POME procedures for evaluation and has achieved good results[58-61]. By using the data feedback from EndoFLIPⓇ, physicians can make intuitive evaluations of the compliance and dilation of the pylorus, providing a new and objective scheme for research on the effectiveness of G-POME.

**Use of G-POME for congenital hypertrophic pyloric stenosis**

***Background***

Congenital hypertrophic pyloric stenosis (CHPS) is a serious disease that occurs in children younger than 1 year and is the third most common gastric abnormality in newborns and infants. CHPS is caused by pyloric muscle hypertrophy, which leads to pyloric obstruction, and usually presents as severe projectile vomiting after eating[62]. Early and accurate diagnosis and treatment are crucial for children with CHPS. A delay in treatment may result in severe malnutrition, multiple organ dysfunction, and even death.

Since Ramstedt first described CHPS in 1912, surgical pyloromyotomy has been the standard treatment for CHPS. This involves a longitudinal pyloric muscle incision under open abdominal conditions[63]. Open surgery can provide good intraoperative pyloric exposure and good treatment results. However, due to the large external incision and the fact that the abdominal scar grows with the growth of the child, this procedure can significantly impact the child's appearance[64] and may even have negative social and psychological effects. With the development of laparoscopic technology, Alain *et al*[65] attempted laparoscopic treatment of CHPS, namely, laparoscopic pyloromyotomy. From a therapeutic perspective, open surgery and laparoscopic surgery have similar safety and efficacy. However, laparoscopic surgery is increasingly used for the treatment of CHPS due to its better cosmetic results and faster postoperative recovery[66,67]. These findings are also in line with the request of parents for good cosmetic results and complete oral feeding recovery after surgery. However, compared with conventional open surgery, laparoscopic pyloromyotomy slightly increases the risk of mucosal perforation and incomplete pyloric muscle incision[64,68], which may require additional surgery, increasing the risk of secondary surgery or even open surgery.

***Endoscopic pyloromyotomy***

In this context, CHPS patients urgently need safe, effective and cosmetically pleasing treatment. In 2005, Ibarguen-Secchia[69] first reported the use of endoscopic pyloromyotomy in CHPS patients. This procedure involves direct sectioning of the muscle layer through a mucosal incision. Although this procedure is theoretically and technically feasible, a high level of skill and experience is needed for physicians to accurately identify the circular muscle layer and control the length and depth of the endoscopic incision during the operation. The risk of postoperative bleeding and perforation is also greater. In addition, after myotomy, the exposed mucosa and muscle layer are exposed to acidic gastric juice, which may induce ulcers and potentially lead to further obstruction[70,71], ultimately resulting in surgical failure.

***Application of G-POME***

With the emergence and promotion of G-POME, which can also effectively improve pyloric muscle spasm, Liu *et al*[72] applied G-POME to treat CHPS for the first time and achieved good results. Thus, G-POME is a technically feasible, safe, and successful procedure for treating CHPS, but the data available for evaluating the safety and efficacy of G-POME in infants with CHPS are quite limited. Zhang *et al*[73] analyzed 21 patients with CHPS treated with G-POME. All patients successfully underwent G-POME, and on the third day after surgery, oral meglumine diatrizoate was used for upper gastrointestinal radiography, with the contrast agent smoothly passing through the pylorus. During the median follow-up period of 25.5 months, no patients developed vomiting, fever, or gastrointestinal bleeding. Due to its endoscopic operation characteristics, G-POME leaves almost no scar on the skin of the child. Compared with traditional surgical methods (open surgery and laparoscopic surgery), G-POME not only has the advantage of being minimally invasive but can also rapidly improve the child's feeding condition while ensuring efficacy, which is consistent with the expectations of parents.

Compared with those of endoscopic pyloromyotomy performed by Ibarguen-Secchia[69], the risk of full-thickness perforation and bleeding after G-POME is greatly reduced. As the main operation of G-POME is carried out in a submucosal tunnel, after wound closure, full-thickness perforation can be avoided, reducing the risk of postoperative perforation and bleeding. During G-POME, the submucosal and circular muscle layers can be clearly and directly identified by submucosal injection[70], facilitating and increasing the accuracy of myotomy and greatly preventing adverse events. In G-POME, after the myotomy operation is completed, the mucosal incision is closed, thus avoiding direct contact between the gastric acid and the muscle incision and mucosa. The incidence of postoperative adverse reactions (such as ulcers) and failure is lower than that of traditional endoscopic pyloromyotomy. This method not only ensures effective treatment but also is associated with decreased risk.

Unlike the G-POME procedure routinely used for gastroparesis, in the treatment of CHPS, the pyloric muscle is not selectively incised, but a full-thickness pyloric muscle incision is made. An incomplete pyloric muscle incision may lead to uncertain results and clinical recurrence[71]. After G-POME, a nasal jejunal tube is placed in one nostril of the child, with the distal end located approximately 10-15 cm behind the pylorus. Enteral nutritional support is given 6 h after the operation. Another nasal gastric tube is placed in the other nostril, with the distal end located in the stomach, and is connected to an external drainage device to fully discharge gastric juice. If there is no leakage of contrast agent during the 3-day follow-up, the mucosal incision is allowed to recover, and oral enteral nutrition, breast milk, or high-energy milk powder is provided[73].

Compared with those in G-POME routinely used in adults, the gastric wall mucosa and submucosa in infants and young children are immature, which may pose difficulties in establishing a submucosal tunnel. However, due to the limited number of patients currently receiving G-POME for CHPS, the safety of this novel treatment approach in patients of different weights requires further study. In addition, because the gastric cavity of infants is narrow, there is less space for surgery, requiring greater technical skills and experience from the physician performing G-POME. It is recommended that surgeons be prepared for surgical rescue treatment during G-POME.

The application of G-POME in the treatment of CHPS has received relatively little attention. Although satisfactory clinical responses were shown in short-term follow-up, further research is needed to compare the long-term effects of G-POME with those of traditional regimens. Nevertheless, the use of G-POME provides a novel treatment option for CHPS patients.

**G-POME for gastric sleeve strictures**

***Background***

Obesity is a global epidemic whose incidence is increasing with economic development, and the popularity of weight loss surgery is also increasing steadily. Among these methods, laparoscopic sleeve gastrectomy (LSG) has become the most common weight loss surgery[74]. Compared to other weight loss surgeries, such as Roux-en-Y gastric bypass (RYGB), LSG can greatly maintain the continuity of the gastrointestinal tract. As a result, patients who undergo LSG rarely exhibit signs of malabsorption and do not require vitamin supplementation for possible deficiencies after surgery[75].

Although the safety of LSG has been confirmed[76], adverse events such as suture leakage, fistula, and bleeding may still occur after surgery, especially for patients with gastric sleeve stenosis (GSS)[77-79]. GSS is a common complication after LSG, with an incidence rate of approximately 4%. GSS can present with various clinical symptoms, such as dyspepsia, reflux, early satiety, abdominal pain, nausea, and vomiting[75]. These symptoms seriously affect the quality of life and physical health of patients. Therefore, timely and effective treatment is needed for patients with GSS.

***Traditional treatment regimen***

For patients with GSS, the existing treatment options include pneumatic balloon dilation, placement of a full-coverage self-expanding metal stent (FCSEMS), and conversion to a gastric bypass procedure such as RYGB.

Balloon dilation is generally a safe and effective treatment option for GSS after LSG, and it is also the preferred treatment option after GSS occurs. According to the report by Dhorepatil *et al*[80], 67.7% of GSS patients experienced symptomatic relief after a single dilation procedure. After multiple dilations, 93.9% of patients showed improvement in their symptoms. However, it is undeniable that a small proportion of patients do not experience symptomatic relief after balloon dilation.

Fayad *et al*[81] reported the use of FCSEMS for treating GSS after LSG and gastric-intestinal anastomotic stenosis after RYGB. This approach is theoretically feasible, but the clinical effect is not satisfactory. However, there is an unavoidable problem in the application of stents, namely, stent migration. Stent migration may lead to serious adverse events that require further intervention or surgical treatment[82]. Even in patients without stent migration, 53.3% of patients experienced symptom recurrence after stent removal, which is similar to what has been observed when using stents to treat gastroparesis patients.

Patients who develop GSS after LSG are usually reluctant to undergo further invasive surgeries, such as gastroplasty by RYGB. In addition, in a study by Sillén *et al*[75], among 21 GSS patients who underwent surgical conversion to RYGB, nearly 50% reported residual GSS symptoms. Moreover, RYGB patients may experience adverse events such as gastric-intestinal anastomotic stenosis, incisional hernia, and bleeding. Therefore, a minimally invasive, safe and effective method for treating GSS after LSG is urgently needed.

***Application of G-POME***

In 2019, Farha *et al*[83] reported for the first time the application of G-POME in patients who developed GSS after LSG. One patient underwent LSG for two months and subsequently developed symptoms of GSS. Endoscopic examination revealed spiral stenosis at the level of the angular notch. After endoscopic balloon dilation, the patient’s symptoms did not improve. After refusing to undergo RYGB for revision surgery, the patient ultimately underwent G-POME to relieve the stenosis.

During G-POME, the physician established an 8-cm submucosal tunnel and performed a 6-cm myotomy. Before and after myotomy, an EndoFLIPⓇ was used to evaluate the diameter, cross-sectional area, and compliance with the stenosis. The results showed that after myotomy, the diameter, cross-sectional area, and compliance with the stenosis significantly improved. At the follow-up visits, the patient's symptoms had almost completely disappeared. Zhang *et al*[74] reported the results of G-POME in 13 patients with GSS. The authors divided the patients into spiral (*n* = 11) and nonspiral (*n* = 2) GSS groups and evaluated their symptoms using the Gastroparesis Symptom Control Index (GSCI). After a follow-up period of approximately 4-9 months, clinical success was achieved in 10 patients (improvement in symptoms after sufficient intake was restored).

From a technical perspective, G-POME for GSS patients is challenging. G-POME for GSS patients requires the establishment of a tunnel from the cardia to the pylorus and full-thickness myotomy within this tunnel. Typically, the length of the tunnel established in G-POME for gastroparesis patients is approximately 4 cm, while that needed for GSS patients reaches 8 cm[83]; GSS patients require a longer length of myotomy. Technically, G-POME for GSS patients is more accurately described as tunneling or narrow-tube incisions than traditional pyloromyotomy. In addition, the presence of a tortuous gastric sleeve and larger gastric vessels further complicate the procedure, requiring greater technical skills from the endoscopic physician.

Currently, there is no effective evaluation tool for quantifying the response to GSS treatment. In the study by Zhang *et al*[74], the GSCI was used for scoring. Similar to the report by Farha *et al*[83] on the use of G-POME in GSS patients, Janes *et al*[84] also used EndoFLIPⓇ to evaluate the therapeutic effect of airbag dilation in GSS patients. Volumetric three-dimensional computerized tomographic reconstruction of the stomach may also be useful for assessing symptoms in GSS patients[85]. In the future, a more effective protocol for assessing the condition of GSS patients is needed to better evaluate the effectiveness of G-POME and other treatment options for GSS patients.

Based on the limited available research on G-POME for GSS, G-POME appears to be a safe, effective and minimally invasive treatment option for refractory GSS. For patients who do not respond well to balloon dilation, G-POME-guided GSS correction may be a good choice. Due to the potential risks and postoperative adverse events associated with G-POME, we do not recommend it as a first-line treatment for all GSS patients. Additionally, the effectiveness of G-POME may vary depending on the type of GSS, but this requires further objective evaluation through larger studies.

**CONCLUSION**

In the future, further development of G-POME should focus mainly on the following key points: (1) The surgical technique should be optimized for gastroparesis patients to increase clinical efficacy and reduce potential adverse reactions and symptom recurrence after surgery; (2) For more extensive application of G-POME in the treatment of CHPS and GSS, larger sample sizes are needed to further evaluate its effectiveness; and (3) Innovative use of G-POME in the treatment of more upper gastrointestinal system diseases should be carried out. Although identifying more suitable diseases for G-POME may be challenging due to its specificity for the pylorus muscle, as a promising novel approach, G-POME may lead to unexpected changes in the treatment of some upper gastrointestinal diseases. Overall, G-POME is a promising endoscopic treatment technique that is safe and minimally invasive and surpasses surgical procedures, meeting the needs of many patients. While ensuring safety and minimal invasiveness, G-POME has considerable effectiveness in treating gastroparesis, CHPS, and GSS. Currently, G-POME, which is recognized and promoted by many centers, is mainly used to treat refractory gastroparesis and has achieved good clinical results. Several centers are pioneering the use of G-POME in the treatment of CHPS/CHPS and GSS/GSS. Although these studies have shown some effectiveness, due to the small sample sizes reported thus far, we cannot yet make a definitive conclusion about the efficacy of G-POME. Nevertheless, these exciting attempts provide a new perspective for the treatment of CHPS and GSS, and additional centers should invest in related clinical research.

**REFERENCES**

1 **Khashab MA**, Stein E, Clarke JO, Saxena P, Kumbhari V, Chander Roland B, Kalloo AN, Stavropoulos S, Pasricha P, Inoue H. Gastric peroral endoscopic myotomy for refractory gastroparesis: first human endoscopic pyloromyotomy (with video). *Gastrointest Endosc* 2013; **78**: 764-768 [PMID: 24120337 DOI: 10.1016/j.gie.2013.07.019]

2 **Inoue H**, Minami H, Kobayashi Y, Sato Y, Kaga M, Suzuki M, Satodate H, Odaka N, Itoh H, Kudo S. Peroral endoscopic myotomy (POEM) for esophageal achalasia. *Endoscopy* 2010; **42**: 265-271 [PMID: 20354937 DOI: 10.1055/s-0029-1244080]

3 **Chung CS**, Huang TY, Lin CL, Chiang CH, Chen KC, Wu JM, Chen KH, Lee TH, Lin CK, Wang HP. Efficacy and safety of gastric peroral endoscopic myotomy (G-POEM) for refractory gastroparesis: 3-year follow up results. *J Formos Med Assoc* 2022; **121**: 1334-1341 [PMID: 34686412 DOI: 10.1016/j.jfma.2021.08.029]

4 **Rodriguez JH**, Haskins IN, Strong AT, Plescia RL, Allemang MT, Butler RS, Cline MS, El-Hayek K, Ponsky JL, Kroh MD. Per oral endoscopic pyloromyotomy for refractory gastroparesis: initial results from a single institution. *Surg Endosc* 2017; **31**: 5381-5388 [PMID: 28567693 DOI: 10.1007/s00464-017-5619-5]

5 **Jovani M**, Brewer-Gutierrez OI, Ichkhanian Y, Runge TM, Khashab MA. Is two better than one? Alternative techniques for gastric peroral endoscopic myotomy. *Endoscopy* 2021; **53**: 556-557 [PMID: 32818990 DOI: 10.1055/a-1226-6271]

6 **Ichkhanian Y**, Vosoughi K, Aghaie Meybodi M, Jacques J, Sethi A, Patel AA, Aadam AA, Triggs JR, Bapaye A, Dorwat S, Benias P, Chaves DM, Barret M, Law RJ, Browers N, Pioche M, Draganov PV, Kotzev A, Estremera F, Albeniz E, Ujiki MB, Callahan ZM, Itani MI, Brewer OG, Khashab MA. Comprehensive Analysis of Adverse Events Associated with Gastric Peroral Endoscopic Myotomy: An International Multicenter Study. *Surg Endosc* 2021; **35**: 1755-1764 [PMID: 32328824 DOI: 10.1007/s00464-020-07570-z]

7 **Stojilkovic T**, Staudinger K, Dennis J. A Systematic Review of the Long-Term Clinical Success of Gastric Peroral Endoscopic Myotomy for Refractory Gastroparesis. *Cureus* 2023; **15**: e39709 [PMID: 37398704 DOI: 10.7759/cureus.39709]

8 **Benias PC**, Khashab MA. Gastric Peroral Endoscopic Pyloromyotomy Therapy for Refractory Gastroparesis. *Curr Treat Options Gastroenterol* 2017; **15**: 637-647 [PMID: 29030799 DOI: 10.1007/s11938-017-0156-9]

9 **Husťak R**, Vacková Z, Krajciova J, Janicko M, Buncová M, Kieslichová E, Spicak J, Martínek J. Per-oral endoscopic pyloromyotomy (g-poem) for the treatment of gastroparesis - a pilot single-centre study with mid-term follow-up. *Rozhl Chir* 2020; **99**: 116-123 [PMID: 32349495 DOI: 10.33699/PIS.2020.99.3.116-123]

10 **Xue HB**, Fan HZ, Meng XM, Cristofaro S, Mekaroonkamol P, Dacha S, Li LY, Fu XL, Zhan SH, Cai Q. Fluoroscopy-guided gastric peroral endoscopic pyloromyotomy (G-POEM): a more reliable and efficient method for treatment of refractory gastroparesis. *Surg Endosc* 2017; **31**: 4617-4624 [PMID: 28409375 DOI: 10.1007/s00464-017-5524-y]

11 **Khashab MA**, Kumbhari V, Azola A, Zein ME, Messallam AA, Abdelgelil A, Besharati S, Kalloo AN, Saxena P. Intraoperative determination of the adequacy of myotomy length during peroral endoscopic myotomy (POEM): the double-endoscope transillumination for extent confirmation technique (DETECT). *Endoscopy* 2015; **47**: 925-928 [PMID: 25850924 DOI: 10.1055/s-0034-1391900]

12 **Khashab MA**, Benias PC, Swanstrom LL. Endoscopic Myotomy for Foregut Motility Disorders. *Gastroenterology* 2018; **154**: 1901-1910 [PMID: 29454796 DOI: 10.1053/j.gastro.2017.11.294]

13 **Vosoughi K**, Ichkhanian Y, Benias P, Miller L, Aadam AA, Triggs JR, Law R, Hasler W, Bowers N, Chaves D, Ponte-Neto AM, Draganov P, Yang D, El Halabi M, Sanaei O, Brewer Gutierrez OI, Bulat RS, Pandolfino J, Khashab M. Gastric per-oral endoscopic myotomy (G-POEM) for refractory gastroparesis: results from an international prospective trial. *Gut* 2022; **71**: 25-33 [PMID: 33741641 DOI: 10.1136/gutjnl-2020-322756]

14 **Mekaroonkamol P**, Dacha S, Wang L, Li X, Jiang Y, Li L, Li T, Shahnavaz N, Sakaria S, LeVert FE, Keilin S, Willingham F, Christie J, Cai Q. Gastric Peroral Endoscopic Pyloromyotomy Reduces Symptoms, Increases Quality of Life, and Reduces Health Care Use For Patients With Gastroparesis. *Clin Gastroenterol Hepatol* 2019; **17**: 82-89 [PMID: 29660525 DOI: 10.1016/j.cgh.2018.04.016]

15 **Gonzalez JM**, Benezech A, Vitton V, Barthet M. G-POEM with antro-pyloromyotomy for the treatment of refractory gastroparesis: mid-term follow-up and factors predicting outcome. *Aliment Pharmacol Ther* 2017; **46**: 364-370 [PMID: 28504312 DOI: 10.1111/apt.14132]

16 **Hustak R**, Vackova Z, Krajciova J, Spicak J, Kieslichova E, Mares J, Martinek J. Endoscopic clips versus overstitch suturing system device for mucosotomy closure after peroral endoscopic pyloromyotomy (G-POEM): a prospective single-center study. *Surg Endosc* 2022; **36**: 9254-9261 [PMID: 35851820 DOI: 10.1007/s00464-022-09417-1]

17 **Kahaleh M**, Gonzalez JM, Xu MM, Andalib I, Gaidhane M, Tyberg A, Saumoy M, Baptista Marchena AJ, Barthet M. Gastric peroral endoscopic myotomy for the treatment of refractory gastroparesis: a multicenter international experience. *Endoscopy* 2018; **50**: 1053-1058 [PMID: 29649841 DOI: 10.1055/a-0596-7199]

18 **Dacha S**, Mekaroonkamol P, Li L, Shahnavaz N, Sakaria S, Keilin S, Willingham F, Christie J, Cai Q. Outcomes and quality-of-life assessment after gastric per-oral endoscopic pyloromyotomy (with video). *Gastrointest Endosc* 2017; **86**: 282-289 [PMID: 28161449 DOI: 10.1016/j.gie.2017.01.031]

19 **Ragi O**, Jacques J, Branche J, Leblanc S, Vanbiervliet G, Legros R, Pioche M, Rivory J, Chaussade S, Barret M, Wallenhorst T, Barthet M, Kerever S, Gonzalez JM. One-year results of gastric peroral endoscopic myotomy for refractory gastroparesis: a French multicenter study. *Endoscopy* 2021; **53**: 480-490 [PMID: 32575130 DOI: 10.1055/a-1205-5686]

20 **Bechara R**, Onimaru M, Ikeda H, Inoue H. Per-oral endoscopic myotomy, 1000 cases later: pearls, pitfalls, and practical considerations. *Gastrointest Endosc* 2016; **84**: 330-338 [PMID: 27020899 DOI: 10.1016/j.gie.2016.03.1469]

21 **Parsa N**, Friedel D, Stavropoulos SN. POEM, GPOEM, and ZPOEM. *Dig Dis Sci* 2022; **67**: 1500-1520 [PMID: 35366120 DOI: 10.1007/s10620-022-07398-8]

22 **Xu J**, Chen T, Elkholy S, Xu M, Zhong Y, Zhang Y, Chen W, Qin W, Cai M, Zhou P. Gastric Peroral Endoscopic Myotomy (G-POEM) as a Treatment for Refractory Gastroparesis: Long-Term Outcomes. *Can J Gastroenterol Hepatol* 2018; **2018**: 6409698 [PMID: 30425974 DOI: 10.1155/2018/6409698]

23 **Khan HM**, Brar TS, Hasan MK, Kadkhodayan K, Arain MA, Hayat M, Farooq A, Singh G, Yang D. Prospective study on the efficacy of endoscopic through-the-scope tack and suture system for gastric peroral endoscopic myotomy mucosal incision site closure. *Endosc Int Open* 2023; **11**: E187-E192 [PMID: 36845274 DOI: 10.1055/a-1978-6842]

24 **Camilleri M**, Parkman HP, Shafi MA, Abell TL, Gerson L; American College of Gastroenterology. Clinical guideline: management of gastroparesis. *Am J Gastroenterol* 2013; **108**: 18-37; quiz 38 [PMID: 23147521 DOI: 10.1038/ajg.2012.373]

25 **Lacy BE**, Parkman HP, Camilleri M. Chronic nausea and vomiting: evaluation and treatment. *Am J Gastroenterol* 2018; **113**: 647-659 [PMID: 29545633 DOI: 10.1038/s41395-018-0039-2]

26 **Sanders KM**, Kito Y, Hwang SJ, Ward SM. Regulation of Gastrointestinal Smooth Muscle Function by Interstitial Cells. *Physiology (Bethesda)* 2016; **31**: 316-326 [PMID: 27488743 DOI: 10.1152/physiol.00006.2016]

27 **Herring BP**, Hoggatt AM, Gupta A, Griffith S, Nakeeb A, Choi JN, Idrees MT, Nowak T, Morris DL, Wo JM. Idiopathic gastroparesis is associated with specific transcriptional changes in the gastric muscularis externa. *Neurogastroenterol Motil* 2018; **30**: e13230 [PMID: 29052298 DOI: 10.1111/nmo.13230]

28 **Grover M**, Bernard CE, Pasricha PJ, Parkman HP, Gibbons SJ, Tonascia J, Koch KL, McCallum RW, Sarosiek I, Hasler WL, Nguyen LAB, Abell TL, Snape WJ, Kendrick ML, Kellogg TA, McKenzie TJ, Hamilton FA, Farrugia G; NIDDK Gastroparesis Clinical Research Consortium (GpCRC). Diabetic and idiopathic gastroparesis is associated with loss of CD206-positive macrophages in the gastric antrum. *Neurogastroenterol Motil* 2017; **29** [PMID: 28066953 DOI: 10.1111/nmo.13018]

29 **Pasricha PJ**, Camilleri M, Hasler WL, Parkman HP. White Paper AGA: Gastroparesis: Clinical and Regulatory Insights for Clinical Trials. *Clin Gastroenterol Hepatol* 2017; **15**: 1184-1190 [PMID: 28410896 DOI: 10.1016/j.cgh.2017.04.011]

30 **Revicki DA**, Rentz AM, Dubois D, Kahrilas P, Stanghellini V, Talley NJ, Tack J. Gastroparesis Cardinal Symptom Index (GCSI): development and validation of a patient reported assessment of severity of gastroparesis symptoms. *Qual Life Res* 2004; **13**: 833-844 [PMID: 15129893 DOI: 10.1023/B:QURE.0000021689.86296.e4]

31 **Tougas G**, Eaker EY, Abell TL, Abrahamsson H, Boivin M, Chen J, Hocking MP, Quigley EM, Koch KL, Tokayer AZ, Stanghellini V, Chen Y, Huizinga JD, Rydén J, Bourgeois I, McCallum RW. Assessment of gastric emptying using a low fat meal: establishment of international control values. *Am J Gastroenterol* 2000; **95**: 1456-1462 [PMID: 10894578 DOI: 10.1111/j.1572-0241.2000.02076.x]

32 **Jung HK**, Choung RS, Locke GR 3rd, Schleck CD, Zinsmeister AR, Szarka LA, Mullan B, Talley NJ. The incidence, prevalence, and outcomes of patients with gastroparesis in Olmsted County, Minnesota, from 1996 to 2006. *Gastroenterology* 2009; **136**: 1225-1233 [PMID: 19249393 DOI: 10.1053/j.gastro.2008.12.047]

33 **Williams PA**, Nikitina Y, Kedar A, Lahr CJ, Helling TS, Abell TL. Long-term effects of gastric stimulation on gastric electrical physiology. *J Gastrointest Surg* 2013; **17**: 50-5; discussion p.55-6 [PMID: 22956404 DOI: 10.1007/s11605-012-2020-5]

34 **Kelly KA**. Gastric emptying of liquids and solids: roles of proximal and distal stomach. *Am J Physiol* 1980; **239**: G71-G76 [PMID: 6996495 DOI: 10.1152/ajpgi.1980.239.2.G71]

35 **Rao AS**, Camilleri M. Review article: metoclopramide and tardive dyskinesia. *Aliment Pharmacol Ther* 2010; **31**: 11-19 [PMID: 19886950 DOI: 10.1111/j.1365-2036.2009.04189.x]

36 **Acosta A**, Camilleri M. Prokinetics in gastroparesis. *Gastroenterol Clin North Am* 2015; **44**: 97-111 [PMID: 25667026 DOI: 10.1016/j.gtc.2014.11.008]

37 **Richards RD**, Davenport K, McCallum RW. The treatment of idiopathic and diabetic gastroparesis with acute intravenous and chronic oral erythromycin. *Am J Gastroenterol* 1993; **88**: 203-207 [PMID: 8424421]

38 **Mekaroonkamol P**, Patel V, Shah R, Li B, Luo H, Shen S, Chen H, Shahnavaz N, Dacha S, Keilin S, Willingham FF, Christie J, Cai Q. Association between duration or etiology of gastroparesis and clinical response after gastric per-oral endoscopic pyloromyotomy. *Gastrointest Endosc* 2019; **89**: 969-976 [PMID: 30653937 DOI: 10.1016/j.gie.2018.12.023]

39 **Sharma A**, Coles M, Parkman HP. Gastroparesis in the 2020s: New Treatments, New Paradigms. *Curr Gastroenterol Rep* 2020; **22**: 23 [PMID: 32193707 DOI: 10.1007/s11894-020-00761-7]

40 **Bromer MQ**, Friedenberg F, Miller LS, Fisher RS, Swartz K, Parkman HP. Endoscopic pyloric injection of botulinum toxin A for the treatment of refractory gastroparesis. *Gastrointest Endosc* 2005; **61**: 833-839 [PMID: 15933684 DOI: 10.1016/s0016-5107(05)00328-7]

41 **Shen S**, Luo H, Vachaparambil C, Mekaroonkamol P, Abdelfatah MM, Xu G, Chen H, Xia L, Shi H, Keilin S, Willingham F, Christie J, Lin E, Cai Q. Gastric peroral endoscopic pyloromyotomy versus gastric electrical stimulation in the treatment of refractory gastroparesis: a propensity score-matched analysis of long term outcomes. *Endoscopy* 2020; **52**: 349-358 [PMID: 32084672 DOI: 10.1055/a-1111-8566]

42 **Shada AL**, Dunst CM, Pescarus R, Speer EA, Cassera M, Reavis KM, Swanstrom LL. Laparoscopic pyloroplasty is a safe and effective first-line surgical therapy for refractory gastroparesis. *Surg Endosc* 2016; **30**: 1326-1332 [PMID: 26293794 DOI: 10.1007/s00464-015-4385-5]

43 **Khashab MA**, Besharati S, Ngamruengphong S, Kumbhari V, El Zein M, Stein EM, Tieu A, Mullin GE, Dhalla S, Nandwani MC, Singh V, Canto MI, Kalloo AN, Clarke JO. Refractory gastroparesis can be successfully managed with endoscopic transpyloric stent placement and fixation (with video). *Gastrointest Endosc* 2015; **82**: 1106-1109 [PMID: 26253017 DOI: 10.1016/j.gie.2015.06.051]

44 **Liang GG**, Zhang QK, Zhang GX, Liu MC. Therapeutic effect of a temporary transpyloric stent in refractory post-surgical gastroparesis: a case report. *BMC Surg* 2019; **19**: 27 [PMID: 30813940 DOI: 10.1186/s12893-019-0490-z]

45 **Mohan BP**, Chandan S, Jha LK, Khan SR, Kotagiri R, Kassab LL, Ravikumar NPG, Bhogal N, Chandan OC, Bhat I, Hewlett AT, Jacques J, Ponnada S, Asokkumar R, Adler DG. Clinical efficacy of gastric per-oral endoscopic myotomy (G-POEM) in the treatment of refractory gastroparesis and predictors of outcomes: a systematic review and meta-analysis using surgical pyloroplasty as a comparator group. *Surg Endosc* 2020; **34**: 3352-3367 [PMID: 31583465 DOI: 10.1007/s00464-019-07135-9]

46 **Landreneau JP**, Strong AT, El-Hayek K, Tu C, Villamere J, Ponsky JL, Kroh MD, Rodriguez JH. Laparoscopic pyloroplasty versus endoscopic per-oral pyloromyotomy for the treatment of gastroparesis. *Surg Endosc* 2019; **33**: 773-781 [PMID: 30019220 DOI: 10.1007/s00464-018-6342-6]

47 **Reja M**, Mishra A, Tyberg A, Andalib I, Martínez GM, Zamarripa F, Gaidhane M, Nieto J, Kahaleh M. Gastric Peroral Endoscopic Myotomy: A Specific Learning Curve. *J Clin Gastroenterol* 2022; **56**: 339-342 [PMID: 34009842 DOI: 10.1097/MCG.0000000000001537]

48 **Mekaroonkamol P**, Shah R, Cai Q. Outcomes of per oral endoscopic pyloromyotomy in gastroparesis worldwide. *World J Gastroenterol* 2019; **25**: 909-922 [PMID: 30833798 DOI: 10.3748/wjg.v25.i8.909]

49 **Khashab MA**, Ngamruengphong S, Carr-Locke D, Bapaye A, Benias PC, Serouya S, Dorwat S, Chaves DM, Artifon E, de Moura EG, Kumbhari V, Chavez YH, Bukhari M, Hajiyeva G, Ismail A, Chen YI, Chung H. Gastric per-oral endoscopic myotomy for refractory gastroparesis: results from the first multicenter study on endoscopic pyloromyotomy (with video). *Gastrointest Endosc* 2017; **85**: 123-128 [PMID: 27354102 DOI: 10.1016/j.gie.2016.06.048]

50 **Malik Z**, Kataria R, Modayil R, Ehrlich AC, Schey R, Parkman HP, Stavropoulos SN. Gastric Per Oral Endoscopic Myotomy (G-POEM) for the Treatment of Refractory Gastroparesis: Early Experience. *Dig Dis Sci* 2018; **63**: 2405-2412 [PMID: 29468376 DOI: 10.1007/s10620-018-4976-9]

51 **Jacques J**, Pagnon L, Hure F, Legros R, Crepin S, Fauchais AL, Palat S, Ducrotté P, Marin B, Fontaine S, Boubaddi NE, Clement MP, Sautereau D, Loustaud-Ratti V, Gourcerol G, Monteil J. Peroral endoscopic pyloromyotomy is efficacious and safe for refractory gastroparesis: prospective trial with assessment of pyloric function. *Endoscopy* 2019; **51**: 40-49 [PMID: 29895073 DOI: 10.1055/a-0628-6639]

52 **Mekaroonkamol P**, Tiankanon K, Rerknimitr R. A New Paradigm Shift in Gastroparesis Management. *Gut Liver* 2022; **16**: 825-839 [PMID: 35670120 DOI: 10.5009/gnl210309]

53 **Zhang WG**, Chai NL, Zhai YQ, Linghu EQ, Li HK. Long-term outcomes of peroral endoscopic myotomy in achalasia patients with a minimum follow-up of 7 years. *Chin Med J (Engl)* 2020; **133**: 996-998 [PMID: 32187047 DOI: 10.1097/CM9.0000000000000735]

54 **Podboy AJ**, Hwang JH, Rivas H, Azagury D, Hawn M, Lau J, Kamal A, Friedland S, Triadafilopoulos G, Zikos T, Clarke JO. Long-term outcomes of per-oral endoscopic myotomy compared to laparoscopic Heller myotomy for achalasia: a single-center experience. *Surg Endosc* 2021; **35**: 792-801 [PMID: 32157405 DOI: 10.1007/s00464-020-07450-6]

55 **Shanker A**, Bashashati M. Measurement of Pyloric Pressures in Gastroparesis: Stiff Competition from EndoFLIP™. *Dig Dis Sci* 2021; **66**: 2475-2477 [PMID: 32945984 DOI: 10.1007/s10620-020-06603-w]

56 **Watts LS**, Baker JR, Lee AA, Harer K, Bowers N, Law R, Hasler WL. Impact of gastric per-oral endoscopic myotomy on static and dynamic pyloric function in gastroparesis patients. *Neurogastroenterol Motil* 2020; **32**: e13892 [PMID: 32542920 DOI: 10.1111/nmo.13892]

57 **McCurdy GA**, Gooden T, Weis F, Mubashir M, Rashid S, Raza SM, Morris J, Cai Q. Gastric peroral endoscopic pyloromyotomy (G-POEM) in patients with refractory gastroparesis: a review. *Therap Adv Gastroenterol* 2023; **16**: 17562848231151289 [PMID: 37007216 DOI: 10.1177/17562848231151289]

58 **Mavrogenis G**, Spanomanoli A, Bazerbachi F. Initial experience of G-POEM in Greece performed with a scissor-type knife and monitored by endoluminal functional imaging. *Ann Gastroenterol* 2022; **35**: 102 [PMID: 34987296 DOI: 10.20524/aog.2021.0673]

59 **Verga MC**, Mazza S, Azzolini F, Cereatti F, Conti CB, Drago A, Soro S, Elvo B, Grassia R. Gastric per-oral endoscopic myotomy: Indications, technique, results and comparison with surgical approach. *World J Gastrointest Surg* 2022; **14**: 12-23 [PMID: 35126859 DOI: 10.4240/wjgs.v14.i1.12]

60 **Snape WJ**, Lin MS, Agarwal N, Shaw RE. Evaluation of the pylorus with concurrent intraluminal pressure and EndoFLIP in patients with nausea and vomiting. *Neurogastroenterol Motil* 2016; **28**: 758-764 [PMID: 26813266 DOI: 10.1111/nmo.12772]

61 **Malik Z**, Sankineni A, Parkman HP. Assessing pyloric sphincter pathophysiology using EndoFLIP in patients with gastroparesis. *Neurogastroenterol Motil* 2015; **27**: 524-531 [PMID: 25712043 DOI: 10.1111/nmo.12522]

62 **Chiarenza SF**, Bleve C, Escolino M, Esposito C, Beretta F, Cheli M, Scuderi MG, Di Benedetto V, Casadio G, Marzaro M, Gambino M, Conforti A, Pini Prato A, Molinaro F, Gerocarni Nappo S, Caione P, Mendoza-Sagaon M. Guidelines of the Italian Society of Videosurgery (SIVI) in Infancy for the minimally invasive treatment of Hypertrophic Pyloric Stenosis in neonates and infants. *Pediatr Med Chir* 2020; **42** [PMID: 33140632 DOI: 10.4081/pmc.2020.243]

63 **Kethman WC**, Harris AHS, Hawn MT, Wall JK. Trends and surgical outcomes of laparoscopic versus open pyloromyotomy. *Surg Endosc* 2018; **32**: 3380-3385 [PMID: 29340829 DOI: 10.1007/s00464-018-6060-0]

64 **Staerkle RF**, Lunger F, Fink L, Sasse T, Lacher M, von Elm E, Marwan AI, Holland-Cunz S, Vuille-Dit-Bille RN. Open versus laparoscopic pyloromyotomy for pyloric stenosis. *Cochrane Database Syst Rev* 2021; **3**: CD012827 [PMID: 33686649 DOI: 10.1002/14651858.CD012827.pub2]

65 **Alain JL**, Grousseau D, Terrier G. Extramucosal pyloromyotomy by laparoscopy. *Surg Endosc* 1991; **5**: 174-175 [PMID: 1839574 DOI: 10.1007/BF02653256]

66 **Dewberry LC**, Vuille-Dit-Bille RN, Kulungowski AM, Somme S. A Single Surgeon Laparoscopic Duodenoduodenostomy Case Series for Congenital Duodenal Obstruction in an Academic Setting. *J Laparoendosc Adv Surg Tech A* 2018; **28**: 1517-1519 [PMID: 30016184 DOI: 10.1089/lap.2018.0215]

67 **Obrist NM**, Tschuor C, Breitenstein S, Vuille-Dit-Bille RN, Soll C. Appendectomy in Switzerland: how is it done? *Updates Surg* 2019; **71**: 375-380 [PMID: 30982171 DOI: 10.1007/s13304-019-00654-z]

68 **Tam PKH**, Chung PHY, St Peter SD, Gayer CP, Ford HR, Tam GCH, Wong KKY, Pakarinen MP, Davenport M. Advances in paediatric gastroenterology. *Lancet* 2017; **390**: 1072-1082 [PMID: 28901937 DOI: 10.1016/S0140-6736(17)32284-5]

69 **Ibarguen-Secchia E**. Endoscopic pyloromyotomy for congenital pyloric stenosis. *Gastrointest Endosc* 2005; **61**: 598-600 [PMID: 15812419 DOI: 10.1016/s0016-5107(05)00075-1]

70 **Kawai M**, Peretta S, Burckhardt O, Dallemagne B, Marescaux J, Tanigawa N. Endoscopic pyloromyotomy: a new concept of minimally invasive surgery for pyloric stenosis. *Endoscopy* 2012; **44**: 169-173 [PMID: 22271027 DOI: 10.1055/s-0031-1291475]

71 **Yang T**, Li L, Zou Y. Endoscopic pyloromyotomy for congenital pyloric stenosis. *Gastrointest Endosc* 2015; **82**: 766 [PMID: 26385284 DOI: 10.1016/j.gie.2015.05.038]

72 **Liu ZQ**, Li QL, Liu JB, Liu HF, Ye H, Fang Y, Zhou PH. Peroral pyloromyotomy for the treatment of infantile hypertrophic pyloric stenosis. *Endoscopy* 2020; **52**: E122-E123 [PMID: 31652470 DOI: 10.1055/a-1022-4274]

73 **Zhang H**, Liu Z, Ma L, Li Q, Huang Y, Dong K, Ye H, Liu J, Liu H, Ren X, Yang H, Hou C, Ge K, Wang H, Zhou P, Fang Y. Gastric Peroral Endoscopic Pyloromyotomy for Infants With Congenital Hypertrophic Pyloric Stenosis. *Am J Gastroenterol* 2023; **118**: 465-474 [PMID: 36002919 DOI: 10.14309/ajg.0000000000001973]

74 **Zhang LY**, Canto MI, Schweitzer MA, Khashab MA, Kumbhari V. Gastric per-oral endoscopic myotomy (G-POEM) for the treatment of gastric sleeve stenosis: a feasibility and safety study. *Endoscopy* 2022; **54**: 376-381 [PMID: 34225370 DOI: 10.1055/a-1544-4923]

75 **Sillén L**, Andersson E, Olbers T, Edholm D. Obstruction after Sleeve Gastrectomy, Prevalence, and Interventions: a Cohort Study of 9,726 Patients with Data from the Scandinavian Obesity Surgery Registry (SOReg). *Obes Surg* 2021; **31**: 4701-4707 [PMID: 34392476 DOI: 10.1007/s11695-021-05574-9]

76 **Carr P**, Keighley T, Petocz P, Blumfield M, Rich GG, Cohen F, Soni A, Maimone IR, Fayet-Moore F, Isenring E, Marshall S. Efficacy and safety of endoscopic sleeve gastroplasty and laparoscopic sleeve gastrectomy with 12+ months of adjuvant multidisciplinary support. *BMC Prim Care* 2022; **23**: 26 [PMID: 35123409 DOI: 10.1186/s12875-022-01629-7]

77 **Zellmer JD**, Mathiason MA, Kallies KJ, Kothari SN. Is laparoscopic sleeve gastrectomy a lower risk bariatric procedure compared with laparoscopic Roux-en-Y gastric bypass? A meta-analysis. *Am J Surg* 2014; **208**: 903-10; discussion 909-10 [PMID: 25435298 DOI: 10.1016/j.amjsurg.2014.08.002]

78 **Rosenthal RJ**; International Sleeve Gastrectomy Expert Panel, Diaz AA, Arvidsson D, Baker RS, Basso N, Bellanger D, Boza C, El Mourad H, France M, Gagner M, Galvao-Neto M, Higa KD, Himpens J, Hutchinson CM, Jacobs M, Jorgensen JO, Jossart G, Lakdawala M, Nguyen NT, Nocca D, Prager G, Pomp A, Ramos AC, Rosenthal RJ, Shah S, Vix M, Wittgrove A, Zundel N. International Sleeve Gastrectomy Expert Panel Consensus Statement: best practice guidelines based on experience of >12,000 cases. *Surg Obes Relat Dis* 2012; **8**: 8-19 [PMID: 22248433 DOI: 10.1016/j.soard.2011.10.019]

79 **Vilallonga R**, Himpens J, van de Vrande S. Laparoscopic management of persistent strictures after laparoscopic sleeve gastrectomy. *Obes Surg* 2013; **23**: 1655-1661 [PMID: 23702907 DOI: 10.1007/s11695-013-0993-0]

80 **Dhorepatil AS**, Cottam D, Surve A, Medlin W, Zaveri H, Richards C, Cottam A. Is pneumatic balloon dilation safe and effective primary modality of treatment for post-sleeve gastrectomy strictures? A retrospective study. *BMC Surg* 2018; **18**: 52 [PMID: 30068333 DOI: 10.1186/s12893-018-0381-8]

81 **Fayad L**, Simsek C, Oleas R, Ichkhanian Y, Fayad GE, Ngamreungphong S, Schweitzer M, Oberbach A, Kalloo AN, Khashab MA, Kumbhari V. Safety and Efficacy of Endoscopically Secured Fully Covered Self-Expandable Metallic Stents (FCSEMS) for Post-Bariatric Complex Stenosis. *Obes Surg* 2019; **29**: 3484-3492 [PMID: 31254212 DOI: 10.1007/s11695-019-04021-0]

82 **Eubanks S**, Edwards CA, Fearing NM, Ramaswamy A, de la Torre RA, Thaler KJ, Miedema BW, Scott JS. Use of endoscopic stents to treat anastomotic complications after bariatric surgery. *J Am Coll Surg* 2008; **206**: 935-8; discussion 938-9 [PMID: 18471727 DOI: 10.1016/j.jamcollsurg.2008.02.016]

83 **Farha J**, Fayad L, Kadhim A, Şimşek C, Badurdeen DS, Ichkhanian Y, Itani MI, Kalloo AN, Khashab MA, Kumbhari V. Gastric Per-Oral Endoscopic Myotomy (G-POEM) for the Treatment of Gastric Stenosis Post-Laparoscopic Sleeve Gastrectomy (LSG). *Obes Surg* 2019; **29**: 2350-2354 [PMID: 31001761 DOI: 10.1007/s11695-019-03893-6]

84 **Janes L**, Platt K, Watts L, Schulman AR. Objective assessment of luminal diameter and distensibility by an impedance planimetry system before and after pneumatic dilation in gastric sleeve stenosis. *VideoGIE* 2022; **7**: 172-174 [PMID: 35585900 DOI: 10.1016/j.vgie.2022.01.015]

85 **Hanssen A**, Plotnikov S, Acosta G, Nuñez JT, Haddad J, Rodriguez C, Petrucci C, Hanssen D, Hanssen R. 3D Volumetry and its Correlation Between Postoperative Gastric Volume and Excess Weight Loss After Sleeve Gastrectomy. *Obes Surg* 2018; **28**: 775-780 [PMID: 28914408 DOI: 10.1007/s11695-017-2927-8]

**Footnotes**

**Conflict-of-interest statement:** All the authors report no relevant conflicts of interest for this article.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** December 19, 2023

**First decision:** January 9, 2024

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B


Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Jankovic K, Serbia **S-Editor:** Lin C **L-Editor:** A **P-Editor:**

**Figure Legends**



**Figure 1 Diagnosis of gastroparesis.**

**Table 1 Innovation in gastric peroral endoscopic myotomy**

|  |  |  |
| --- | --- | --- |
|  | **Traditional methods** | **Interesting Innovation** |
| Position of initial mucosal incision | Great curvature/posterior wall of the stomach | Both the greater and lesser curvatures of the stomach |
| Identification of the PMR | Pull the endoscope out of the tunnel | Placing an inner clip or using double endoscope |
| Pyloromyotomy | Selective myotomy | More extensive myotomy |

PMR: Pyloric muscle ring.

**Table 2** **Traditional medication treatment methods**

|  |  |
| --- | --- |
| **Typical traditional drugs for gastroparesis** | **Disadvantages** |
| Metoclopramide | Severe extrapyramidal side effects |
| Domperidone | Cardiovascular-related adverse effects |
| Erythromycin | Rapid tolerance |
| Ondansetron | Insignificant effect on gastric emptying |
| Prucalopride and Cisapride |
| Phenothiazines and Atropine |